The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

NCI is moving forward with a plan to evaluate multi-cancer early detection tests, a technology that is rapidly making inroads into the healthcare system.  

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Paul Goldberg
Editor & Publisher
Alice Tracey
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthPodcast

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
By Robert A. Winn, Otis W. Brawley and Preston Willett
Cancer Policy

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

NIH announced Jan. 29 that “Basic Experimental Studies Involving Humans,” also called BESH, will no longer be considered clinical trials and will therefore no longer be subject to the requirements under the NIH definition of a clinical trial, including registration and reporting requirements in ClinicalTrials.gov.
By Jacquelyn Cobb
PodcastThe Directors

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
By Paul Goldberg and Claire Marie Porter
Clinical Roundup

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

Moderna and Merck announced median five-year follow-up data from the phase IIb KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with high-risk melanoma (stage 3/4) following complete resection. 
Byline
Paul Goldberg
Editor & Publisher
Alice Tracey
Alice Tracey
Reporter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account